Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 août 2018 07h00 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Participate in Two Healthcare Investor Conferences in September

HOUSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
07 août 2018 16h05 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Reports Second Quarter 2018 Financial Results

HOUSTON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
06 août 2018 07h00 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Appoints Dr. Thierry Darcis as General Manager of Europe to Lead the Anticipated Launch of BPX-501

HOUSTON, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
31 juil. 2018 07h00 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018

HOUSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
16 juil. 2018 16h25 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer

HOUSTON, July 16, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
30 mai 2018 07h00 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

HOUSTON, May 30, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
29 mai 2018 07h00 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Appoints Shane Ward as General Counsel

HOUSTON, May 29, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
17 mai 2018 09h20 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association

HOUSTON, May 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
15 mai 2018 07h00 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy

HOUSTON, May 15, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
08 mai 2018 16h01 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results

HOUSTON, May 08, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...

Page précédente

Page suivante